These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1945 related articles for article (PubMed ID: 30679318)

  • 21. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study.
    Bilici A; Uysal M; Menekse S; Akin S; Yildiz F; Turan M; Sezgin Goksu S; Beypinar I; Sakalar T; Değirmenci M; Erdem D; Basaran G; Olmez OF; Avci N; Tural D; Sakin A; Turker S; Demir A; Temiz S; Kaplan MA; Dogan M; Tanriverdi O; Bilgetekin I; Cinkir HY; Acikgoz O; Paydas S; Uslu R; Turhal S
    Cancer Invest; 2022 Feb; 40(2):199-209. PubMed ID: 34894960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR
    Bardia A; Modi S; Oliveira M; Cortes J; Campone M; Ma B; Dirix L; Weise A; Hewes B; Diaz-Padilla I; Han Y; Deshpande P; Samant TS; Lorenc KR; He W; Su F; Chavez-MacGregor M
    Clin Cancer Res; 2020 Dec; 26(24):6417-6428. PubMed ID: 32998962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Petrakova K; Blackwell KL; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Mondal S; Su F; Miller M; Elmeliegy M; Germa C; O'Shaughnessy J
    Ann Oncol; 2018 Jul; 29(7):1541-1547. PubMed ID: 29718092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
    Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
    Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.
    Toi M; Shao Z; Hurvitz S; Tseng LM; Zhang Q; Shen K; Liu D; Feng J; Xu B; Wang X; Lee KS; Ng TY; Ridolfi A; Noel-Baron F; Ringeisen F; Jiang Z
    Breast Cancer Res; 2017 Apr; 19(1):47. PubMed ID: 28399902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial.
    Fullana B; Morales S; Petit A; Alay A; Verdaguer H; Climent F; Navarro-Perez V; Cejuela M; Galvan P; Gumà A; Llombart-Cussac A; Cordero D; Casanovas O; Prat A; Gil-Gil M; Pernas S
    Sci Rep; 2024 Oct; 14(1):23626. PubMed ID: 39384801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
    Bachelot T; McCool R; Duffy S; Glanville J; Varley D; Fleetwood K; Zhang J; Jerusalem G
    Breast Cancer Res Treat; 2014 Jan; 143(1):125-33. PubMed ID: 24272078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
    Noguchi S; Masuda N; Iwata H; Mukai H; Horiguchi J; Puttawibul P; Srimuninnimit V; Tokuda Y; Kuroi K; Iwase H; Inaji H; Ohsumi S; Noh WC; Nakayama T; Ohno S; Rai Y; Park BW; Panneerselvam A; El-Hashimy M; Taran T; Sahmoud T; Ito Y
    Breast Cancer; 2014 Nov; 21(6):703-14. PubMed ID: 23404211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.
    Krop I; Abramson V; Colleoni M; Traina T; Holmes F; Garcia-Estevez L; Hart L; Awada A; Zamagni C; Morris PG; Schwartzberg L; Chan S; Gucalp A; Biganzoli L; Steinberg J; Sica L; Trudeau M; Markova D; Tarazi J; Zhu Z; O'Brien T; Kelly CM; Winer E; Yardley DA
    Clin Cancer Res; 2020 Dec; 26(23):6149-6157. PubMed ID: 32988969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry.
    Knapen LM; Geurts SME; Ibragimova KIE; Croes S; Vriens BEPJ; van den Berkmortel FWPJ; Dercksen MW; van de Wouw AJ; Pepels MJAE; de Fallois AOJ; Lobbezoo DJA; de Boer M; Tjan-Heijnen VCG
    Breast; 2019 Apr; 44():46-51. PubMed ID: 30641299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
    Hortobagyi GN; Chen D; Piccart M; Rugo HS; Burris HA; Pritchard KI; Campone M; Noguchi S; Perez AT; Deleu I; Shtivelband M; Masuda N; Dakhil S; Anderson I; Robinson DM; He W; Garg A; McDonald ER; Bitter H; Huang A; Taran T; Bachelot T; Lebrun F; Lebwohl D; Baselga J
    J Clin Oncol; 2016 Feb; 34(5):419-26. PubMed ID: 26503204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer.
    Okazaki M; Horimoto Y; Tanabe M; Ichikawa Y; Tokuda E; Arakawa A; Kobayashi T; Saito M
    Med Oncol; 2018 Mar; 35(4):48. PubMed ID: 29520681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.
    Sánchez-Bayona R; Lopez de Sa A; Jerez Gilarranz Y; Sanchez de Torre A; Alva M; Echavarria I; Moreno F; Tolosa P; Herrero Lopez B; de Luna A; Lema L; Gamez Casado S; Madariaga A; López-Tarruella S; Manso L; Bueno-Muiño C; Garcia-Saenz JA; Ciruelos E; Martin M
    Breast Cancer Res Treat; 2024 Aug; 206(3):551-559. PubMed ID: 38703285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment.
    Dhakal A; Matthews CM; Levine EG; Salerno KE; Zhang F; Takabe K; Early AP; Edge SB; O'Connor T; Khoury T; Young JS; Opyrchal M
    Clin Breast Cancer; 2018 Dec; 18(6):e1401-e1405. PubMed ID: 29778787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
    Beck JT; Hortobagyi GN; Campone M; Lebrun F; Deleu I; Rugo HS; Pistilli B; Masuda N; Hart L; Melichar B; Dakhil S; Geberth M; Nunzi M; Heng DY; Brechenmacher T; El-Hashimy M; Douma S; Ringeisen F; Piccart M
    Breast Cancer Res Treat; 2014 Feb; 143(3):459-67. PubMed ID: 24362951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
    Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
    Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 98.